Utility of characteristic ‘Weak to Absent’ INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0463|123|7|618-628

ISSN： 0903-4641

Source： APMIS (ELECTRONIC), Vol.123, Iss.7, 2015-07, pp. : 618-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SMARCB1/INI1/BAF47‐ deficient pleural malignant mesothelioma with rhabdoid features

By  

PATHOLOGY INTERNATIONAL, Vol. 68, Iss. 2, 2018-02 ,pp. : 128-132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glial papillary tumour of the spinal cord with SMARCB1/INI1‐loss and favourable long‐term outcome

By  

NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Vol. 44, Iss. 2, 2018-02 ,pp. : 229-232

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 897-900

John Wiley & Sons Inc

Access to resources Recommend Favorite

Frequent co‐inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours

By  

HISTOPATHOLOGY, Vol. 67, Iss. 1, 2015-07 ,pp. : 121-129

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2448-2456

John Wiley & Sons Inc

Access to resources Recommend Favorite